KEI Staff's blog

Kassy Perry, speaking on behalf of ?, opposing AB 463, on transparency of drug R&D costs and subsidies

During the debate of California bill AB 463, on the Pharmaceutical Cost Transparency Act of 2015, Kassy Perry was using Twitter to attack the bill, posting links to and repeating pharmaceutical industry talking points. Who is Kassy Perry? A founder of Perry Communications, a Sacramento public relations and lobbying firm. This is her Twitter profile:

Sony referred to "WIPO treaty for blind as "stalking horse" to "denigrate the rights of copyright owners"

In the new Wikileaks archives of leaked Sony documents (Link here), there is a memo (, which describes Sony Pictures Entertainment (SPE) concern over the proposed WIPO treaty for copyright exceptions for persons who are blind or have other disabilities. The memo, undated in the Wikileaks archives, but probably written in 2009, included the following passages:

2014 Oct 3 version: Regional Comprehensive Economic Partnership, Japan IPR proposals, RCEP

(More KEI RCEP leaks here:

Attached is a leaked version of Japan's October 3, 2014 proposals for intellectual property for the Regional Comprehensive Economic Partnership.

Patents with government interests, by disease, 2010 to 2013

The attached PDF file provides counts on the number of patents with various search terms in the specification (spec/"search term"), and the number of those patents that declare either government rights in the patents (govt/government), an assignment to the US government (an/"united states of america"), or both. The complete counts are in the PDF file. The queries were done by Claire Cassedy on December 5, 2014.

Rajasingh on India-US dispute over patents on dasatinib, a drug to treat leukemia

link to video: See also:

Video script:

My name is Elizabeth Rajasingh.

I want to talk about a trade dispute between India and the United States, involving patents on a drug for leukemia.

Comments to USTR on the Out-of-Cycle Review for India due October 31, 2014.

Ambassador Michael Froman wants to block compulsory licenses on drug patents in India

KEI welcomes the Gilead HCV licenses, as a step to expand access to treatments. Notes challenges that remain

Today Gilead announced it will provide seven generic drug manufacturers licenses to make and sell two drugs that are used in combination to treat the Hepatitis C Virus (HCV) in 91 developing countries.

Money speaks: USTR releases letters from Congress backing PhRMA on exclusive rights biologic test data in TPP

As part of a partial response to FOIA request, USTR has provided KEI with copies of 13 letters sent by members of Congress, from July 27, 2011 to August 8, 2013, on the topic of biologic drug test data provisions in the TPP negotiation. We had obtained several but not all of these letters earlier from a variety of sources, including from PhRMA's web page -- where some had been proudly displayed. (See link below).

Were there letters on the other side? Yes, three. (see below).

With the FOIA request, we have also obtained the responses to the letters.

KEI's comments on Special 301, March 7, 2014

KEI’s Additional Comments Special 301

March 7, 2014

James Love, Knowledge Ecology International

Docket # USTR-2013-0040

These comments supplement KEI’s February 7, 2014 written submission (Also available here:, and, and our February 24, 2014 oral testimony, and provide also comment or reply to the written or oral submissions by others.

1. India is an important source of affordable medicines.

ITC Investigation No. 332-543, KEI written statement, February 14, 2014 hearing

The KEI written statement for the February 14, 2014 US International Trade Commission (USITC) hearing on India is attached here.

Among other things, the Statement includes 15 pages describing US compulsory licenses.

We also have a video play list with more than 9 hours of the Feb 12 and Feb 14 hearing.

James Love on India bashing at USTR's Feb 24, 2014 Special 301 hearing

Claire Cassedy did this interview at the KEI offices, following the February 24, 2014 USTR hearing on the Special 301.

Blogs and Press coverage of Pharma/Medicine device industry lobbying on South Africa patent reform (pharmagate)

Boseley, Sarah. 17 January 2014. "South African pharma firms accused of planning to delay patents law reform." The Guardian.

De Wet, Phillip. 17 January 2014. "Motsoaledi: Big pharma's 'satanic' plot is genocide." Mail & Guardian.

GE's Thaddeus Burns wrote to US Ambassador Betty King requesting US postpone Marrakesh Diplomatic Conference

Thaddeus Burns of GE spent months trying to derail the WIPO treaty for the blind negotiations

NGOs, academics evaluate four USTR negotiators in TPP IPR negotiations

KEI has asked 21 persons following the TPP IPR negotiations, what they thought of four of the USTR negotiators, including:

  • Ambassador and USTR head Michael Froman,
  • TPP Chief negotiator Barbara Weisel
  • Assistant USTR for Intellectual Property and Innovation Stanford McCoy, and
  • Deputy Assistant USTR for Intellectual Property and Innovation Probir Mehta.

Audiovisual Materials in the Classroom and the WIPO treaty for copyright exceptions for persons with disabilities

Fedro De Tomassi

My name is Fedro De Tomassi. I am a student at St. Olaf College, class of 2014, and next week I will be a volunteer (as a guide and interpreter) at the Diplomatic Conference to Conclude a Treaty to Facilitate Access to Published Works by Visually Impaired Persons and Persons with Print Disabilities (June 17 to 28, 2013 – Marrakesh, Morocco)

Syndicate content